<p>Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - 免費報告) - Cantor Fitzgerald 的研究分析師在 8 月 12 日星期一發布的研究報告中提高了對 Lineage Cell Therapeutics 股票 2024 財年盈利的預期。Cantor Fitzgerald 分析師 K. Kluska 現預計該公司全年每股盈利為（$0.18），高於他們先前的預期（$0.20）。對於 Lineage Cell Therapeutics 當前全年盈利的共識預期為每股（$0.12）。</p>
<p>另外，HC Wainwright 在 5 月 6 日星期一的研究報告中重申了對 Lineage Cell Therapeutics 股票的&#34;買入&#34;評級，並設定了$7.00 的目標價。</p>
<p><strong>查看我們關於 Lineage Cell Therapeutics 的最新報告</strong></p>
<h2>Lineage Cell Therapeutics 股價下跌 1.3%</h2>
<p>Lineage Cell Therapeutics 股票週三開盤價為$0.83。Lineage Cell Therapeutics 的 52 周最低價為$0.82，52 周最高價為$1.61。該股市值為 1.5659 億美元，市盈率為-5.92，β值為 1.29。</p>
<p>Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - 獲取免費報告) 於 8 月 8 日星期四發佈了其財報。公司本季度每股盈利（EPS）為（$0.03），超過了每股（$0.04）的共識預期。本季度公司營收為 141 萬美元，超過了分析師預期的 128 萬美元。Lineage Cell Therapeutics 的淨利潤率為-295.59%，淨資產收益率為-34.92%。</p>
<h2>Lineage Cell Therapeutics 的機構交易</h2>
<p>一些機構投資者和對沖基金最近調整了他們對該公司的持股。XTX Topco Ltd 在第二季度購入了 Lineage Cell Therapeutics 的新股份，價值 6.1 萬美元。Renaissance Technologies LLC 在第二季度增加了對 Lineage Cell Therapeutics 的持股，持股量增長了 10.0%，現在擁有公司股票的 583,622 股，價值 58.2 萬美元。Rhumbline Advisers 在第二季度增加了對 Lineage Cell Therapeutics 的持股，持股量增長了 15.1%，現在擁有公司股票的 132,491 股，價值 13.2 萬美元。紐約梅隆銀行在第二季度增加了對 Lineage Cell Therapeutics 的持股，持股量增長了 35.7%，現在擁有公司股票的 435,958 股，價值 43.5 萬美元。最後，Comerica 銀行在第一季度將其對 Lineage Cell Therapeutics 的持股增加了 84,745.8%，現在擁有公司股票的 250,295 股，價值 37 萬美元。目前 62.47% 的股份由機構投資者持有。</p>
<h2>Lineage Cell Therapeutics 公司簡介（獲取免費報告）</h2>
<p>Lineage Cell Therapeutics, Inc 是一家臨牀階段的生物技術公司，致力於為美國和國際市場未滿足的醫療需求開發新型細胞療法。該公司開發了 OpRegen，一種同種異體視網膜色素上皮細胞替代療法，目前正在進行乾性年齡相關性黃斑變性治療的 2a 期臨牀試驗；OPC1，一種同種異體寡突觸前體細胞療法，目前正在進行多中心 1/2a 期臨牀試驗，用於治療頸椎脊髓損傷；以及 VAC，一種同種異體抗原呈遞樹突狀細胞癌症免疫療法，目前正在進行 I 期臨牀試驗，用於治療非小細胞肺癌。</p>
<h2>參見</h2>
<ul>
<li>我們喜歡的五隻股票，比 Lineage Cell Therapeutics 更好</li>
<li>如何投資最佳加拿大股票</li>
<li>Instacart 股票以利潤和人工智能推動增長</li>
<li>基礎材料股票投資</li>
<li>PROCEPT BioRobotics 是否是外科機器人領域的下一個大事件？</li>
<li>股票情緒分析：它是如何工作的</li>
<li>波動市場中穩定性的前三隻股息支付股票</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成，旨在為讀者提供最快速和準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 這一隻股票就是你需要的...（來自市場幕後）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ5"/></p>
<h2>您現在是否應該投資$1,000 購買 Lineage Cell Therapeutics 股票？</h2>
<p>在考慮購買 Lineage Cell Therapeutics 股票之前，您可能需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的五隻股票...而 Lineage Cell Therapeutics 不在名單上。</p>
<p>儘管 Lineage Cell Therapeutics 目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

LCTX

<p>Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - 免費報告) - Cantor Fitzgerald 的研究分析師在 8 月 12 日星期一發布的研究報告中提高了他們對 Lineage Cell Therapeutics 股票 2024 財年盈利的預估。 Cantor Fitzgerald 分析師 K</p>

<p>Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 earnings estimates for shares of Lineage Cell Therapeutics in a research report issued on Monday, August 12th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($0.18) per share for the year, up from their previous estimate of ($0.20). The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.12) per share.</p>
<div class="lb-trans"><p>Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - 免費報告) - Cantor Fitzgerald 的研究分析師在 8 月 12 日星期一發布的研究報告中提高了對 Lineage Cell Therapeutics 股票 2024 財年盈利的預期。Cantor Fitzgerald 分析師 K. Kluska 現預計該公司全年每股盈利為（$0.18），高於他們先前的預期（$0.20）。對於 Lineage Cell Therapeutics 當前全年盈利的共識預期為每股（$0.12）。</p>
</div><p>Separately, HC Wainwright restated a &#34;buy&#34; rating and set a $7.00 target price on shares of Lineage Cell Therapeutics in a research report on Monday, May 6th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 5 月 6 日星期一的研究報告中重申了對 Lineage Cell Therapeutics 股票的&#34;買入&#34;評級，並設定了$7.00 的目標價。</p>
</div><p><strong>View Our Latest Report on Lineage Cell Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Lineage Cell Therapeutics 的最新報告</strong></p>
</div><h2>Lineage Cell Therapeutics Stock Down 1.3 %</h2>
<div class="lb-trans"><h2>Lineage Cell Therapeutics 股價下跌 1.3%</h2>
</div><p>Lineage Cell Therapeutics stock opened at $0.83 on Wednesday. Lineage Cell Therapeutics has a 52-week low of $0.82 and a 52-week high of $1.61. The stock has a market cap of $156.59 million, a price-to-earnings ratio of -5.92 and a beta of 1.29.</p>
<div class="lb-trans"><p>Lineage Cell Therapeutics 股票週三開盤價為$0.83。Lineage Cell Therapeutics 的 52 周最低價為$0.82，52 周最高價為$1.61。該股市值為 1.5659 億美元，市盈率為-5.92，β值為 1.29。</p>
</div><p>Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. The company had revenue of $1.41 million for the quarter, compared to analysts' expectations of $1.28 million. Lineage Cell Therapeutics had a negative net margin of 295.59% and a negative return on equity of 34.92%.</p>
<div class="lb-trans"><p>Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - 獲取免費報告) 於 8 月 8 日星期四發佈了其財報。公司本季度每股盈利（EPS）為（$0.03），超過了每股（$0.04）的共識預期。本季度公司營收為 141 萬美元，超過了分析師預期的 128 萬美元。Lineage Cell Therapeutics 的淨利潤率為-295.59%，淨資產收益率為-34.92%。</p>
</div><h2>Institutional Trading of Lineage Cell Therapeutics</h2>
<div class="lb-trans"><h2>Lineage Cell Therapeutics 的機構交易</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in Lineage Cell Therapeutics in the 2nd quarter worth $61,000. Renaissance Technologies LLC grew its position in shares of Lineage Cell Therapeutics by 10.0% during the second quarter. Renaissance Technologies LLC now owns 583,622 shares of the company's stock worth $582,000 after purchasing an additional 53,022 shares in the last quarter. Rhumbline Advisers raised its stake in Lineage Cell Therapeutics by 15.1% during the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company's stock valued at $132,000 after purchasing an additional 17,411 shares during the period. Bank of New York Mellon Corp lifted its holdings in Lineage Cell Therapeutics by 35.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company's stock worth $435,000 after purchasing an additional 114,762 shares in the last quarter. Finally, Comerica Bank boosted its stake in Lineage Cell Therapeutics by 84,745.8% in the 1st quarter. Comerica Bank now owns 250,295 shares of the company's stock worth $370,000 after purchasing an additional 250,000 shares during the period. 62.47% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近調整了他們對該公司的持股。XTX Topco Ltd 在第二季度購入了 Lineage Cell Therapeutics 的新股份，價值 6.1 萬美元。Renaissance Technologies LLC 在第二季度增加了對 Lineage Cell Therapeutics 的持股，持股量增長了 10.0%，現在擁有公司股票的 583,622 股，價值 58.2 萬美元。Rhumbline Advisers 在第二季度增加了對 Lineage Cell Therapeutics 的持股，持股量增長了 15.1%，現在擁有公司股票的 132,491 股，價值 13.2 萬美元。紐約梅隆銀行在第二季度增加了對 Lineage Cell Therapeutics 的持股，持股量增長了 35.7%，現在擁有公司股票的 435,958 股，價值 43.5 萬美元。最後，Comerica 銀行在第一季度將其對 Lineage Cell Therapeutics 的持股增加了 84,745.8%，現在擁有公司股票的 250,295 股，價值 37 萬美元。目前 62.47% 的股份由機構投資者持有。</p>
</div><h2>Lineage Cell Therapeutics Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Lineage Cell Therapeutics 公司簡介（獲取免費報告）</h2>
</div><p>Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.</p>
<div class="lb-trans"><p>Lineage Cell Therapeutics, Inc 是一家臨牀階段的生物技術公司，致力於為美國和國際市場未滿足的醫療需求開發新型細胞療法。該公司開發了 OpRegen，一種同種異體視網膜色素上皮細胞替代療法，目前正在進行乾性年齡相關性黃斑變性治療的 2a 期臨牀試驗；OPC1，一種同種異體寡突觸前體細胞療法，目前正在進行多中心 1/2a 期臨牀試驗，用於治療頸椎脊髓損傷；以及 VAC，一種同種異體抗原呈遞樹突狀細胞癌症免疫療法，目前正在進行 I 期臨牀試驗，用於治療非小細胞肺癌。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Lineage Cell Therapeutics</li>
<li>How to Invest in the Best Canadian Stocks</li>
<li>Instacart Stock Gains Momentum with Profits and AI-Powered Carts</li>
<li>Basic Materials Stocks Investing</li>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Top 3 Dividend-Paying Stocks for Stability in Volatile Markets</li>
</ul>
<div class="lb-trans"><h2>參見</h2>
<ul>
<li>我們喜歡的五隻股票，比 Lineage Cell Therapeutics 更好</li>
<li>如何投資最佳加拿大股票</li>
<li>Instacart 股票以利潤和人工智能推動增長</li>
<li>基礎材料股票投資</li>
<li>PROCEPT BioRobotics 是否是外科機器人領域的下一個大事件？</li>
<li>股票情緒分析：它是如何工作的</li>
<li>波動市場中穩定性的前三隻股息支付股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成，旨在為讀者提供最快速和準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ This One stock is all you need... (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 這一隻股票就是你需要的...（來自市場幕後）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9149&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Lineage Cell Therapeutics right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資$1,000 購買 Lineage Cell Therapeutics 股票？</h2>
</div><p>Before you consider Lineage Cell Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買 Lineage Cell Therapeutics 股票之前，您可能需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已確定了頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的五隻股票...而 Lineage Cell Therapeutics 不在名單上。</p>
</div><p>While Lineage Cell Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Lineage Cell Therapeutics 目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

分析師對 Lineage Cell Therapeutics, Inc.（NYSEAMERICAN:LCTX）2024 財年收益的預期